Bempedoic Acid: A Monotherapy for Cardiovascular Disease

The mechanism that Bempedoic acid reduces LDL by is different from statins and therefore it's meant to have a lower incidence of muscle related adverse events. The biggest sticking point to this point though is a lack of data on hard endpoints, so cardiovascular outcomes has been unclear. A 1% reduction in cardiovascular events is often considered quite reasonable for cardiovascular treatments but the problem with these composite endpoints is they do hide some of the important information. NICE had no significant effects on fatal or non-fatal stroke and no significant changes to the levels of death from either cardiovascular events or from any cause.